{"meta":{"query_hash":"a4e20e8ca8af","filters":{"venue":"American Journal of Cancer"},"cohort_total":7,"direct_labels_cover":0,"predictions_cover":7,"exported":7,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/a4e20e8ca8af","api":"https://metacan.xera.ac/api/v1/cohort?venue=American+Journal+of+Cancer"},"results":[{"id":"W1488429601","doi":"10.2165/00024669-200201030-00003","title":"Hypercalcemia of Malignancy","year":2002,"lang":"de","type":"article","venue":"American Journal of Cancer","topic":"Bone health and treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Hamilton Regional Laboratory Medicine Program","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Malignancy; Calcitonin; Cancer; Calcium metabolism; Internal medicine; Endocrinology; Calcium","score_opus":0.021391365166986708,"score_gpt":0.31980981705348044,"score_spread":0.29841845188649374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1488429601","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.42737958,0.15813452,0.0027411,0.012968599,0.0017221236,0.000335935,0.0038885043,0.0004672789,0.39236242],"genre_scores_gemma":[0.9534084,0.025114173,0.00096122734,0.0018847396,0.0012788886,0.00006580119,0.0019237332,0.000026317026,0.015336788],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99971265,0.000049269434,0.00004678815,0.000028622499,0.00009087463,0.000071704926],"domain_scores_gemma":[0.9997452,0.000060134564,0.00006088021,0.000027224223,0.000054871438,0.000051735664],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021685791,0.0002997812,0.00028897237,0.0012816126,0.0005463293,0.000722648,0.00042332913,0.00048226738,0.0063341022],"category_scores_gemma":[0.0013320785,0.00011101578,0.00031447996,0.0014994672,0.00039460175,0.00041473776,0.0004923562,0.00062490103,0.0011160854],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020250198,0.00028873928,0.50909656,0.0015129591,0.0002637763,0.083777085,0.00088124984,0.00027196112,0.01793029,0.01570888,0.05674025,0.31150317],"study_design_scores_gemma":[0.00014252936,0.00034776592,0.39967522,0.0004706372,0.00025202424,0.2554772,0.00068663585,0.0003502746,0.0062183333,0.006489828,0.3298412,0.000048396174],"about_ca_topic_score_codex":0.00318621,"about_ca_topic_score_gemma":0.0037430795,"teacher_disagreement_score":0.0063341022,"about_ca_system_score_codex":0.0005699239,"about_ca_system_score_gemma":0.0011205625,"threshold_uncertainty_score":0.02118969},"labels":[],"label_agreement":null},{"id":"W1805832649","doi":"10.2165/00024669-200605040-00002","title":"Epidermal Growth Factor Receptor Antagonists in Pancreatic Cancer","year":2006,"lang":"en","type":"article","venue":"American Journal of Cancer","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Erlotinib; Cetuximab; Pancreatic cancer; Gemcitabine; Medicine; Epidermal growth factor receptor; EGFR inhibitors; Oncology; Gefitinib; Erlotinib Hydrochloride; Internal medicine; Cancer; Pharmacology; Colorectal cancer","score_opus":0.019959407913621396,"score_gpt":0.36015438891479007,"score_spread":0.3401949810011687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1805832649","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.49420103,0.46881914,0.000828669,0.00745448,0.00096290244,0.000080680584,0.00040127954,0.00015830153,0.027093494],"genre_scores_gemma":[0.7604947,0.22529326,0.0009004759,0.0017945919,0.0005704612,0.000079703175,0.00059986627,0.00002053444,0.01024644],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9999044,0.00003248003,0.000012010464,0.0000073673027,0.000017685952,0.000026046077],"domain_scores_gemma":[0.99988234,0.000040849536,0.000023509916,0.000008168271,0.00001231266,0.000032817294],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048052985,0.00020447356,0.0005455038,0.0002805933,0.00020780382,0.00047791487,0.0001714394,0.00034236605,0.0019334088],"category_scores_gemma":[0.00023329575,0.000110093235,0.00032208627,0.00035424076,0.000142183,0.00028257183,0.00017313012,0.0009846508,0.0003754198],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017576745,0.0018524202,0.014709218,0.0013065625,0.0004581128,0.0021692708,0.0001270951,0.0016211256,0.058654495,0.0029957339,0.02513055,0.8733987],"study_design_scores_gemma":[0.013901755,0.04379402,0.11883187,0.00069038686,0.0019069613,0.023236431,0.0006040199,0.00263926,0.08475063,0.0033424294,0.70621306,0.00008908257],"about_ca_topic_score_codex":0.0005054532,"about_ca_topic_score_gemma":0.0019347675,"teacher_disagreement_score":0.0019334088,"about_ca_system_score_codex":0.0004033129,"about_ca_system_score_gemma":0.0005263175,"threshold_uncertainty_score":0.006467879},"labels":[],"label_agreement":null},{"id":"W1988990009","doi":"10.2165/00024669-200504020-00005","title":"Fluorouracil Formulations for the Treatment of Actinic Keratosis","year":2005,"lang":"en","type":"article","venue":"American Journal of Cancer","topic":"Nonmelanoma Skin Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; University of Toronto; Mediprobe Research (Canada); Sunnybrook Health Science Centre","funders":"","keywords":"Actinic keratosis; Medicine; Dermatology; Imiquimod; Cryotherapy; Keratosis; Fluorouracil; Erythema; Acitretin; Rosacea; Cryosurgery; Adverse effect; Clinical trial; Surgery; Acne; Chemotherapy; Psoriasis; Pharmacology; Internal medicine","score_opus":0.027949960004267214,"score_gpt":0.36492402977898963,"score_spread":0.33697406977472244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988990009","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8888545,0.09970923,0.0003868834,0.00063522405,0.00023534545,0.00045773483,0.00018416576,0.000012158071,0.009524863],"genre_scores_gemma":[0.96053714,0.035566702,0.0004719308,0.00015434856,0.0001248585,0.000082683044,0.00010118913,0.000002836723,0.0029583927],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9996158,0.00024151155,0.000021264806,0.000021977557,0.00005969774,0.000039797316],"domain_scores_gemma":[0.9994886,0.00032318634,0.000077308316,0.000019959365,0.00003558837,0.000055293935],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00076246756,0.00023238575,0.00034206492,0.00048551182,0.000378554,0.00031269452,0.00022116613,0.00042114974,0.0033197603],"category_scores_gemma":[0.0010669205,0.00011561896,0.0004448703,0.00034456467,0.00025760112,0.00032062366,0.0001641313,0.00067614304,0.00015859128],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17262352,0.015633404,0.0049369168,0.0059749573,0.0009965373,0.001019492,0.0007792074,0.00074845145,0.075618096,0.0029546705,0.0042595244,0.7144551],"study_design_scores_gemma":[0.07858922,0.61755955,0.07131073,0.0024340271,0.0035605887,0.0044476576,0.0015865926,0.0008360971,0.11076152,0.00091725297,0.10789774,0.00009902171],"about_ca_topic_score_codex":0.0019820065,"about_ca_topic_score_gemma":0.0052796733,"teacher_disagreement_score":0.0033197603,"about_ca_system_score_codex":0.0005373143,"about_ca_system_score_gemma":0.00057197956,"threshold_uncertainty_score":0.011105716},"labels":[],"label_agreement":null},{"id":"W2059413299","doi":"10.2165/00024669-200504010-00003","title":"The Oral NK1 Antagonist Aprepitant for Prevention of Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy","year":2005,"lang":"en","type":"article","venue":"American Journal of Cancer","topic":"Nausea and vomiting management","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Aprepitant; Antiemetic; Chemotherapy-induced nausea and vomiting; Medicine; Vomiting; Nausea; NK1 receptor antagonist; Ondansetron; Anesthesia; Chemotherapy; Regimen; Granisetron; Pharmacology; Internal medicine; Oncology; Receptor; Substance P","score_opus":0.011766599754773512,"score_gpt":0.32034852165469835,"score_spread":0.30858192189992484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2059413299","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98305213,0.013113561,0.00025978906,0.0007902458,0.000120159,0.0000874492,0.00005581329,0.000028670058,0.0024923142],"genre_scores_gemma":[0.99458295,0.0037474446,0.00061130995,0.0003700267,0.00014451743,0.00003320834,0.00008588447,0.000003908649,0.00042083394],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99988604,0.000043232816,0.0000162005,0.000007607292,0.000025709038,0.000021190557],"domain_scores_gemma":[0.9997038,0.00008753914,0.000087491746,0.000008761092,0.000023558841,0.000088774825],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020908973,0.00017636198,0.0008434147,0.00013340093,0.00023378448,0.00024211346,0.00016128876,0.0002445441,0.00063028245],"category_scores_gemma":[0.0012970367,0.000105455314,0.00019978778,0.00018933773,0.000121155645,0.00024393678,0.0001571017,0.0006588987,0.00010783166],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09238216,0.002804744,0.20180109,0.0010536533,0.00066538504,0.004279633,0.0003157128,0.0013529384,0.03222951,0.00031506643,0.007698643,0.65510154],"study_design_scores_gemma":[0.017146802,0.08560269,0.8425461,0.00033769273,0.0011529002,0.017635541,0.00044224944,0.0045105508,0.011897274,0.0004178083,0.01824996,0.00006045473],"about_ca_topic_score_codex":0.0006683188,"about_ca_topic_score_gemma":0.0020327999,"teacher_disagreement_score":0.0008434147,"about_ca_system_score_codex":0.00028031785,"about_ca_system_score_gemma":0.00050343847,"threshold_uncertainty_score":0.0021085143},"labels":[],"label_agreement":null},{"id":"W2088738945","doi":"10.2165/00024669-200302060-00003","title":"Pharmacologic Management of Painful Oncology Procedures in Pediatrics","year":2003,"lang":"en","type":"article","venue":"American Journal of Cancer","topic":"Pediatric Pain Management Techniques","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Hospital for Sick Children","funders":"","keywords":"Medicine; Anesthesia; Sedation; Prilocaine; Lidocaine; Propofol; Fentanyl; Alfentanil; Ketamine; Midazolam","score_opus":0.014473809833069897,"score_gpt":0.36465601077635007,"score_spread":0.3501822009432802,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2088738945","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.59998167,0.31430313,0.0068023917,0.012120836,0.0014675107,0.00021744632,0.00021623037,0.00015849764,0.06473232],"genre_scores_gemma":[0.87374765,0.1090747,0.009183074,0.002459789,0.0017323388,0.00017064843,0.00012467534,0.000020793776,0.0034862596],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998092,0.00006594232,0.000023075725,0.000010339923,0.000058468253,0.000032897147],"domain_scores_gemma":[0.999509,0.00016085713,0.00018665145,0.00000948501,0.00004675008,0.000087232176],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025114225,0.00016160774,0.00028140075,0.000331009,0.00042101627,0.00028748243,0.00020400288,0.00028081995,0.001985629],"category_scores_gemma":[0.0015212969,0.00008155369,0.00019182726,0.0002542359,0.00015399554,0.0001840462,0.00018085263,0.000797911,0.00028122103],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000994823,0.003181406,0.09012886,0.002069468,0.00025466457,0.014979872,0.00058271654,0.0007046807,0.018272515,0.003696163,0.019554656,0.8455803],"study_design_scores_gemma":[0.0010046434,0.013353655,0.57310295,0.0038500493,0.00096072594,0.18264154,0.002732868,0.0021347592,0.029908085,0.002221501,0.18803711,0.00005216827],"about_ca_topic_score_codex":0.0006187261,"about_ca_topic_score_gemma":0.0021084063,"teacher_disagreement_score":0.001985629,"about_ca_system_score_codex":0.00026991835,"about_ca_system_score_gemma":0.0007552829,"threshold_uncertainty_score":0.0066426396},"labels":[],"label_agreement":null},{"id":"W2325094700","doi":"10.2165/00024669-200504040-00006","title":"Erlotinib","year":2005,"lang":"de","type":"article","venue":"American Journal of Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Erlotinib; Pharmacology; Internal medicine; Cancer","score_opus":0.00928745523564239,"score_gpt":0.3634912078921711,"score_spread":0.3542037526565287,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2325094700","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.22347622,0.06681995,0.006445452,0.01976649,0.0048481775,0.00107766,0.012824436,0.005750774,0.65899074],"genre_scores_gemma":[0.6100926,0.012702966,0.003343911,0.0053980034,0.00066517683,0.0003408022,0.0116872415,0.0001520435,0.3556173],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.999838,0.000016299875,0.000008507353,0.00003734176,0.00004141745,0.000058567042],"domain_scores_gemma":[0.9999454,0.0000055531455,0.000006933116,0.000009294909,0.000010382738,0.0000224191],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001444687,0.00046264593,0.00067598873,0.00045441248,0.00042684216,0.00060557626,0.0003929441,0.0006453979,0.04689184],"category_scores_gemma":[0.0002696907,0.00013726365,0.0004137671,0.00026940415,0.00014606521,0.00035780435,0.00032796522,0.0010776668,0.020215373],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0065165064,0.0010423467,0.0025591191,0.00066082366,0.00022743322,0.0012999757,0.0000382865,0.00071722874,0.07122956,0.004315836,0.19544184,0.7159509],"study_design_scores_gemma":[0.002617313,0.002561397,0.008051234,0.00012913365,0.00023283261,0.008097356,0.000028905071,0.001186841,0.044665657,0.0013109106,0.9310708,0.00004762905],"about_ca_topic_score_codex":0.0006962917,"about_ca_topic_score_gemma":0.0015161566,"teacher_disagreement_score":0.04689184,"about_ca_system_score_codex":0.00053430366,"about_ca_system_score_gemma":0.00059484184,"threshold_uncertainty_score":0},"labels":[],"label_agreement":null},{"id":"W2334751043","doi":"10.2165/00024669-200403060-00003","title":"Hepatocellular Carcinoma","year":2004,"lang":"en","type":"article","venue":"American Journal of Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto","funders":"","keywords":"Medicine; Hepatocellular carcinoma; Cirrhosis; Hepatitis B; Internal medicine; Gastroenterology; Cancer; Viral hepatitis; Liver cancer","score_opus":0.031933780284345716,"score_gpt":0.27486328875050464,"score_spread":0.24292950846615893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2334751043","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.21229847,0.023284033,0.004355504,0.0063162963,0.0018302222,0.00041508325,0.005288676,0.00070988026,0.7455019],"genre_scores_gemma":[0.79198086,0.01160028,0.0016582645,0.002349654,0.0010059077,0.00015294229,0.0072749746,0.00006470101,0.1839124],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998747,0.000019431018,0.000008700603,0.000012844698,0.000041799074,0.000042450556],"domain_scores_gemma":[0.99984014,0.000016123722,0.000022632388,0.00003240008,0.000043152366,0.000045513003],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001664503,0.00013940272,0.00023952693,0.00086126087,0.0005506775,0.00039576454,0.0001326079,0.00022561158,0.03241387],"category_scores_gemma":[0.00050618965,0.00006828592,0.00028968212,0.00083380815,0.00016901015,0.00026103648,0.00027607867,0.00027999948,0.010716528],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010762895,0.00027082246,0.255062,0.00065140205,0.00017067905,0.016109454,0.00029337924,0.00016064133,0.011809035,0.008329044,0.15549463,0.5505725],"study_design_scores_gemma":[0.00011105435,0.00034893022,0.23195006,0.00022031816,0.00014716129,0.058672674,0.0003945906,0.00031208032,0.0059446064,0.0022985905,0.69956607,0.000033843222],"about_ca_topic_score_codex":0.0023461932,"about_ca_topic_score_gemma":0.0030230584,"teacher_disagreement_score":0.03241387,"about_ca_system_score_codex":0.00033424897,"about_ca_system_score_gemma":0.00041285457,"threshold_uncertainty_score":0.10843521},"labels":[],"label_agreement":null}]}